Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS
Status:
Terminated
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter efficacy
and safety trial to evaluate Mycograb®. Subjects will be randomized to receive either
Mycograb® (dosed 1 mg/kg) or placebo during the first week of induction therapy (amphotericin
B plus 5-flucytosine) via a central line or peripheral venous line twice daily for 7
consecutive days. The total duration of the study will be approximately 24 months.